Government Agents Gave Cover for Roundup’s Birth Defects


 

Government Agents Gave Cover for Roundup’s Birth Defects

by Heidi Stevenson

Part 1, Industry Studies Prove Roundup Causes Birth Defects, told about the general types of games played in the coverup of Roundup's ability to cause birth defects. Here in Part 2, we discuss the specifics. It's stunning how blatant they are. Most things should be obvious to anyone with a 7th grade education.

We'd like to believe that government agencies tasked with assuring that our health and the environment are protected would do that. But as we can see in a scientific review by Germany's Federal Office for Consumer Protection and Food Safety (German acronym of BVL), which was tasked by the European Union's Commission to review research on glyphosate (brand name Roundup), that's far from reality.

Specific Errors Made by Government Agents

First, here is a table, produced by the reviewers referenced here[1], that shows the results of selected industry-financed studies that are discussed below:

Study author and date Submitter company Experimental animal/exposure route Doses used
mg/kg bw/d
Effects found Dose-related effects/Statistical significance
Suresh, 1993 Feinchemie Rabbits/gavage 0, 20, 100, 500 Dilated heart Linear dose-response relationship. Significantly elevated at all doses, including low dose
        Unspecified "major visceral malformations" Linear dose-response relationship. Increased in all treatment groups, significantly increased at highest dose
        Extra 13th rib Linear dose-response relationship. Statistically significant increase at highest dose
Brooker et al., 1991 Monsanto/Cheminova Rabbits/gavage 0, 50, 150, 450 Heart malformations (only type specified is interventricular septal defect) Effect found at highest dose. No information provided by Germany on statistical significance
        Embryonic deaths Significant at all doses, though no clear dose/response relationship
Bhide and Patil, 1989 Barclay/Luxan Rabbits/route unstated 0, 125, 250, 500 Heart malformation (ventricular septal defect) Linear dose-response relationship. No statistical analysis provided by authors. Increased heart malformations found in all treatment groups
        Lungs: postcaval lobe absent Linear dose-response relationship. No statistical analysis provided by authors. Dose-dependent increases found in all treatment groups
        Kidneys absent Linear dose-response relationship. No statistical analysis provided by authors. Dose-dependent increases found in all treatment groups
        Rudimentary 14th rib, unilateral No statistical analysis provided by authors. Dose-dependent increases found in mid- and high-dose groups
        Number of viable foetuses per litter decreased and number of non-viable implants increased Linear dose-response relationship in case of non-viable implants. No statistical analysis provided by authors.  Effects found at high dose level.
Tasker et al., 1980 Monsanto/Cheminova Rabbits/gavage 0, 75, 175, 350 Increased number of deaths in dams Linear dose-response relationship. 1, 2, and 10 deaths in low, mid- and high-dose treatment groups respectively (no. of rabbits per group: 16 or 17). 75 mg/kg stated by Germany to be NOAEL
Anon., 1981 Alkaloida Rats and rabbits/oral feeding 0, 10.5, 50.7, 255.3 Increased number of foetal deaths Effect seen at two upper dose levels
Zhu et al., 1984 Barclay Mice/gavage 80, 420, 1050 Germany comments that there is "No evidence of dose-related toxic effects" and "no ... structural malformations" but that description of experiment was "poor" Data not provided by Germany
Brooker et al., 1991 Monsanto/Cheminova Rats/gavage 0, 300, 1000, 3500 Distortions affecting thoracic ribs Dose-dependent increases found in mid- and high-dose groups. Statistically significant at high dose
        Reduced ossification of one or more cranial centres Dose-dependent increases found in mid- and high-dose groups.
        Reduced ossification of sacro-caudal vertebral arches Dose-dependent increases found in mid- and high-dose groups
        Unossified sternebrae Increases found in all treated groups, statistically significant at high dose
        Skeletal variations Dose-dependent increases found in all treated groups, statistically significant in mid-dose and high-dose groups.
Tasker and Rodwell, 1980 Monsanto/Cheminova Rats/gavage 0, 300, 1000, 3500 Unossified sternebrae Increase found at highest dose level
        Unspecified malformations Increase at highest dose level
        No. of viable foetuses per litter and mean foetal weight decreased Effects found at highest dose level
        Early resorption of embryos Data not provided by Germany
Suresh, 1991 Feinchemie Rats/gavage 0, 1000 Increase in delayed ossification (caudal vertebral arch, forelimb proximal and hindlimb distal phalanges) found in treatment group, but increase in delayed ossification of skull found in control group Conflicting data led Germany to conclude that the NOAEL for developmental toxicity was 1000 mg/kg
Bhide, 1986 Barclay/Luxan Rats/gavage 0, 100, 500 No effects found but Germany commented that "serious reporting deficiencies" and lack of statistical analysis led it to consider the study as supplementary information only In spite of lack of reliable data, Germany derived a NOAEL for developmental toxicity of 500 mg/kg
Anon., 1981 Alkaloida Rats and rabbits/oral feeding 22, 103, 544 Germany commented that description of study is so "poor" that it only considered the study as supplementary information. There were "no malformations recorded" and effects on foetuses were "not observed" but it is unclear from Germany's summary whether this was due to poor reporting by the study's authors or if there was an actual absence of effects In spite of lack of reliable data, Germany derived a NOAEL for developmental toxicity of 544 mg/kg

Now we'll look into specific industry-sponsored studies that the BVL reviewed, focusing on their particular findings:

Increased Skeletal, Visceral, and Heart Malformations

A study on rabbits by Suresh found that the number of fetuses with "major visceral anomalies was high in all treated groups". They also found that the percentage of fetuses with dilated hearts was increased at all dosage levels and that skeletal variations, anomalies, and malformations were found, though without a definitive dose-response pattern.

The Germans dismissed this finding by claiming that the actual number of fetuses with dilated hearts was small, that there was no increase at the mid-dose range, that no other soft organ malformations occurred, and that "the supposed consequences of this heart malformation were 'equivocal'".  They also found that the study showed No Observable Adverse Effect Levels (NOAELs).

The reviewers of that paper agree that NOAEL should have been found, but rather than state that it means there is no indication of a problem, they said it means that more studies, and more appropriately-designed ones, need to be done. As they state:

Their comment that the number of foetuses with abnormalities was small merely identifies a shortcoming of the standardised industry studies performed for regulatory purposes. Larger numbers of animals are preferable. If the number of animals used is small, any effect will only be seen in a few animals and statistical significance will be difficult to obtain. This is especially true at lower doses, where observable effects will be smaller and/or less frequent.

Continue to Page 2

Pages :
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.